News - Truvada, Benlysta

Filter

Current filters:

TruvadaBenlysta

Popular Filters

1 to 25 of 45 results

AHF claims victory over FDA on Gilead’s PrEP

19-02-2014

The USA-based AIDS Healthcare Foundation (AHF) says it has won another key legal victory late last week…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaRegulationTruvadaUSA

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

AHF claims victory over FDA in HIV prevention drug case

08-08-2013

The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

AHF demands FDA reversal on use of Gilead's HIV prevention pill for women

06-03-2013

Citing another failed clinical trial in women of the use of Gilead Sciences' (Nasdaq: GILD) AIDS drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationResearchTruvada

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

25-10-2012

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Gilead's Truvada as HIV prevention to carry stronger FDA warning label

14-10-2012

The USA-based non-profit HIV/AIDS advocacy AIDS Healthcare Foundation (AHF) welcomed the news yesterday…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Barriers to overcome in lupus drug development

22-07-2012

It has taken the lupus research community over 50 years to produce a new therapy. Although it is now…

Anthera PharmaceuticalsBenlystaBiotechnologyblisibimodGlaxoSmithKlineImmunologicalsPharmaceuticalResearch

FDA approves Truvada, first drug for reducing the risk of sexually acquired HIV infection

17-07-2012

Despite protests from consumer groups such as the AIDS Healthcare Foundation (AHF), the US Food and Drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

Zacks analysts view progress of GSK bid for Human Genome Sciences

05-06-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) recently announced that the waiting period with respect to…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

1 to 25 of 45 results

Back to top